Wonder if you can predict which pts you can successfully taper off bDMARDs? Abst#1538 from Denmark showed that a neg IgM-RF (OR 0.26) & low Doppler serum score for 24 jts predicted successful discontinuation of bDMARDs at 2yr f/u in RA pts w/ DAS28-CRP<2.6. #ACR20 @RheumNow https://t.co/CbJTguxaoa

Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/qdEpNpzdNs

I am glad now that chloroquine is not available (permanent back order) in Canada as results of high retinal toxicity w chloroquine was sobering & changed my practice. I won’t use it long term @RheumNow #ACR20 @CRASCRRheum abstr#1825 https://t.co/1RQi41uV1B https://t.co/lc9za22Zw1

• https://twitter.com/aliduartemd/status/1325817215095103488

A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI & hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20 @RheumNow

Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0

Dr. N Nikolov #FDA reviews role for rheum meds in #COVID19 and outlines guidance for trial design for CV19 therapeutics #ACR20 @rheumnow https://t.co/0oPvBN5mgF

Study out of China, #ABS1892 shows that patient reported outcomes using self assessments are important in AS T2T and decreasing flare rates #ACR20 @RheumNow. https://t.co/ebGtVUg8IV https://t.co/oXvGxQSjtn

• Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylo…

What are you doing at 12pm today on this #ACR20 Monday? I will be listening to @LCalabreseDO discuss the importance of #empathy in rheumatology @HealioRheum @RheumNow https://t.co/E1cH39z64p

#ABS0597 All PR-COIN centers found telemed visits met provider needs & 18/19 centers believed telemed visits met pedi-rheum pt needs. Reasons for in-person visit included presence of active dz, worsening condition, & parent request/desire. #ACR20 @RheumNow https://t.co/yun6QCv4fX https://t.co/l9BrVMdJEa

• Telemedicine in Pediatric Rheumatology During COVID-19: The PR-COIN Experience …

Abatacept in RA and ILD Patients: Dr Richard Conway (@RichardPAConway) #ACR20 https://t.co/e31VsnXFq5 https://t.co/sCrqLtXFFc

• https://bit.ly/353aM15

The 'triple M' irAEs (myositis/myocarditis/MG): one of the rheumatic irAEs where autoAb are freq pos Nice systematic review: any autoAb+ 61% tested MG+ 59% tested MSA+ in 27% tested (18/67, 11 had myositis alone) @NilashaGhosh @lovetolearn27 @got_rheum #ACR20 ABST1574 @RheumNow https://t.co/utSj8yY0fd

#FDA updates #ACR20 @rheumnow labeling/warning changes: belimumab- mortality removed abatacept - angioedema added baricitinib -hypersensitivity rxn added gabapentin & pregabalin - respiratory depression added

Do you routinely request for HLA-B27 in young patients w/ IBP? @RheumNow #ACR20

Deucravacitinib TYK2i for PsA Phase2b 16wk, Double-blind, Placebo, RCT ⬆️ACR20/50/70 response vs. PBO ⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO *⃣No serious AE @RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/9Klu2aeEj2